Addition of Liraglutide to Patients With Type 2 Diabetes Treated With Multiple Daily Insulin Injections

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 124 participants.

Also called NCT02113332

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 124 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02113332
  • EudraCT 2012-001941-42
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Sweden (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02113332. Randomized; quadruple masking; primary purpose treatment. Start 2013-01 (registry gives no type); primary completion 2014-08 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Addition of Liraglutide to Patients With Type 2 Diabetes Treated With Multiple Daily Insulin Injections
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Liraglutide
Intervention (Drug)
Placebo
Lead sponsor
Vastra Gotaland Region (class: other government)
Collaborator
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct02113332
Content hash
abfe8bccd56d79463ab89ef826b0ab72454021fc9d9377debe2eea5dadf7ceec